Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/04/2022* -- Results Q3 2022 -- -0.13 --
11/04/2022* 08:45 EST Earnings Call Q3 2022 -- -- --
08/04/2022 -- Results Q2 2022 -0.10 -0.12 16.67%
08/04/2022 08:45 EST Earnings Call Q2 2022 -- -- --
05/05/2022 -- Results Q1 2022 -0.11 -0.16 28.96%
05/05/2022 08:45 EST Earnings Call Q1 2022 -- -- --
03/03/2022 -- Results Q4 2021 -0.15 -0.20 24.26%
03/03/2022 08:45 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/04/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/04/2022
Beat/Miss Upgrade
Return Since -24.41%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
URL http://www.arbutusbio.com
Investor Relations URL https://investor.arbutusbio.com
HQ State/Province Pennsylvania
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Nov. 04, 2022 (est.)
Last Earnings Release Aug. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-70.63%
-44.94%
106.1%
-24.16%
-27.42%
27.70%
9.58%
-50.64%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-21.61%
-4.45%
61.78%
272.4%
-50.01%
-9.55%
-70.43%
-61.49%
-27.04%
--
--
--
--
28.09%
434.1%
143.1%
-51.32%
7.30%
4.68%
16.13%
25.06%
-6.73%
3.51%
66.74%
-23.60%
-87.17%
63.37%
16.67%
-79.93%
-17.17%
8.91%
-45.97%
-70.79%
As of September 23, 2022.

Profile

Edit
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
URL http://www.arbutusbio.com
Investor Relations URL https://investor.arbutusbio.com
HQ State/Province Pennsylvania
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Nov. 04, 2022 (est.)
Last Earnings Release Aug. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
MSGR 106485.0 USD 3.06%
JMIGX 487800.0 USD 1.41%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter ABUS Tweets